Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan

Both overall survival (OS) and progression‐free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Etsuko, Sasaki, Yasutsuna, Ohkuma, Ryotaro, Takahashi, Takehiro, Kubota, Yutaro, Ishida, Hiroo, Hamada, Kazuyuki, Kiuchi, Yuji, Tsunoda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272097/
https://www.ncbi.nlm.nih.gov/pubmed/30315613
http://dx.doi.org/10.1111/cas.13831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272097/
https://www.ncbi.nlm.nih.gov/pubmed/30315613
http://dx.doi.org/10.1111/cas.13831

Ejemplares similares